VEGFA and renal cell carcinoma: The cabozantinib tablet formulation (CabometyxTM) was subsequently approved at a dose of 60-mg FBE daily in the USA for the treatment of renal cell carcinoma (RCC) following anti-angiogenic therapy and in the EU following prior VEGF-targeted therapy [4, 5].